期刊
TRENDS IN CELL BIOLOGY
卷 29, 期 10, 页码 820-834出版社
ELSEVIER SCIENCE LONDON
DOI: 10.1016/j.tcb.2019.07.008
关键词
-
类别
资金
- Dutch Cancer Foundation (KWF)
- Netherlands Organisation for Scientific Research (NWO-VICI scheme)
- European Research Council (ERC Consolidator grant)
- Oncode
Poly-(ADP)-ribose polymerase (PARP) inhibition is synthetic lethal with deficiency for homologous recombination (HR), a pathway essential for DNA double-strand break repair. PARP inhibitors (PARPi) therefore hold great promise for the treatment of tumors with disruptive mutations in BRCA1/2 or other HR factors. Unfortunately, PARPi resistance has proved to be a major problem in the clinic. Knowledge about PARPi resistance is expanding quickly, revealing four main mechanisms that alter drug availability, affect (de)PARylation enzymes, restore HR, or restore replication fork stability. We discuss how studies on resistance mechanisms have yielded important insights into the regulation of DNA double-strand break (DSB) repair and replication fork protection, and how these studies could pave the way for novel treatment options to target resistance mechanisms or acquired vulnerabilities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据